tradmap

CLX Financials Clorox

15 years of revenue, profit, cash flow and balance-sheet history through FY2026, from SEC filings — with a computed, factual read of the trend. Updated Overview →

Growth & profitability

  • Revenue has grown 1.1% per year over the past 5 years.
  • Net income has grown slower than revenue (-3.3% vs 1.1% per year).
  • Free cash flow has declined 10.0% per year over the past 5 years.

Financial health

  • Total debt ($5.1B) exceeds cash ($143M); net debt is $4.9B.
  • Total debt has grown faster than revenue (12.7% vs 1.1% per year).
Revenue & net income
$0 $4B $7B 2012 2014 2016 2018 2020 2022 2024 2026
RevenueNet income
Margins (gross / operating / net)
0% 23% 46% 2012 2014 2016 2018 2020 2022 2024 2026
GrossOperatingNet
Return on equity & assets (ROE / ROA)
-401% 134% 668% 0% 2012 2014 2016 2018 2020 2022 2024 2026
ROEROA
Free cash flow (CFO − capex)
$0 $646M $1B 2012 2014 2016 2018 2020 2022 2024 2026
Free cash flow
Cash vs total debt
$0 $3B $5B 2012 2014 2016 2018 2020 2022 2024 2026
CashTotal debt
Cash flow: operating / investing / financing
-$1B $78M $2B $0 2012 2014 2016 2018 2020 2022 2024 2026
OperatingInvestingFinancing

Key annual figures

FYRevenueNet incomeGross MOp MROEROAFCFTotal debtCash
2026 — $601M — — 667.8% 7.7% — $5.1B $143M
2025 $7.1B $824M 45.2% 0.0% 256.7% 14.8% $761M $2.5B $167M
2024 $7.1B $292M 43.0% 0.0% 89.0% 5.1% $483M $2.5B $202M
2023 $7.4B $161M 39.4% 0.0% 73.2% 2.7% $930M $2.5B $367M
2022 $7.1B $471M 35.8% 0.0% 84.7% 7.6% $535M $2.7B $183M
2021 $7.3B $710M 43.6% 0.0% 172.7% 11.2% $945M $2.8B $319M
2020 $6.7B $939M 45.6% 0.0% 103.4% 15.1% $1.3B $2.8B $871M
2019 $6.2B $820M 43.9% 0.0% 146.7% 16.0% $786M $2.7B $111M
2018 — $823M — — 113.4% 16.3% $782M $2.5B $131M
2017 — $701M — — 129.3% 15.3% $634M $2.2B $418M
2016 — $648M — — 218.2% 14.4% $606M $2.3B $401M
2015 — $580M — — 491.5% 14.0% $749M $2.2B $382M
2014 — $558M — — 362.3% 13.1% $630M $2.3B $329M
2013 — $572M — — 391.8% 13.3% $585M $2.4B $299M
2012 — $541M — — -400.7% 12.4% $423M $2.7B $267M

Valuation over time

How the market has priced CLX against its own fundamentals since 2023-03 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.

Price / earnings (P/E)
0.0 59.8 119.7 Mar '23 Sep '23 Mar '24 Sep '24 Mar '25 Sep '25 Mar '26 Sep '26
P/E
Price / sales (P/S)
0.0 1.4 2.9 Mar '23 Sep '23 Mar '24 Sep '24 Mar '25 Sep '25 Mar '26 Sep '26
P/S
Dividend yield (%)
0.0 2.8 5.5 Mar '23 Sep '23 Mar '24 Sep '24 Mar '25 Sep '25 Mar '26 Sep '26
Dividend yield %

Frequently asked questions

Is CLX growing its revenue and profit?

Over the past 5 years, Clorox's revenue has grown 1.1% per year, and net income declined 3.3% per year. These are computed facts, not advice.

How much debt does CLX have?

As of FY2026, Clorox reported $5.1B of total debt against $143M of cash.

What is CLX's profit margin?

In FY2026, gross margin was —, operating margin —, and net margin —.

What is CLX's P/E ratio?

Clorox's P/E (TTM) is 15.82 as of the 2026-11-02 close — market cap ÷ net income over the trailing twelve months where four consecutive quarters are reported, otherwise the latest fiscal year, the same figure as on the CLX stock page. The valuation chart above sets each month-end's price against the latest annual net income instead, so its latest point (about 18.2× as of Nov '26) can differ. These are computed facts, not advice.

Where does this data come from?

All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.

Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), split-adjusted; price return — dividends not reinvested · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.